1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
67148529A6C913DC50025858A001F2131
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/best-practices-distributing-medical-info-physicians-investigators-through-portals-other-means
18
19
203.237.94.109
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Medical Communication

Best Practices in Distributing Medical Info to Investigators and Physicians through Investigator Portals and Other Means

ID: POP-329


Features:

2 Info Graphics

10 Data Graphics

70+ Metrics


Pages: 20


Published: 2020


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Effective Medical Information groups must evaluate and prioritize how they disseminate critical information to a variety of key external stakeholders (such as investigators and physicians) across numerous different channels.

This benchmarking research examines the channels and approaches used by elite pharma companies to distribute medical information to investigators and physicians. This report also probes the usage of specific investigator websites and different content shared by the companies via this medium; website protection strategies; and tools used to access trial data, publications, abstracts and other critical information types.

Industries Profiled:
Pharmaceutical; Biotech; Biopharmaceutical; Medical Device; Health Care; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Allergan; Alnylam Pharmaceuticals; Boehringer Ingelheim; Clovis Oncology; CSL Behring; Dermira; Dova Pharmaceuticals; Edwards Lifesciences; Gilead Sciences; Ipsen; Lexicon Pharmaceuticals; Merck; Mylan; Novartis; Sanofi Genzyme; Sanofi; Sage Therapeutics; Vifor Pharma

Study Snapshot

Best Practices, LLC engaged 24 leaders from 19 pharmaceutical companies in this research through a benchmarking survey. Three-fourths of the study participants serve at the director level and above.

Key topics covered in this report include:

  • Sharing of Clinical Information with Investigators
  • Access to Investigator Website Portal
  • Communication via Investigator Website Portal


Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Slide decks are primary mode to share information: All companies use slide decks to share clinical information with investigators. Other formats are less preferred.
  • IST and clinical trial info shared via website: Companies with websites share more of IST and clinical trial content and less of current/past Congresses, which is different than those without portals.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive Summaryp. 3-5
Research Objectives, Methodology, Study Analysis, and Recommendationsp. 4
Universe of Learningp. 5
II.
Sharing of Clinical Information with Investigatorsp. 6-9
III.
Access to Investigator Website Portalp. 10-14
IV.
Communication via Investigator Website Portalp. 15-16
V.
Participant’s Demographicsp. 17-19
VI.
About Best Practices, LLCp. 20

    List of Charts & Exhibits

    I. Sharing of Clinical Information with Investigators

    • Formats for sharing clinical development publications, abstracts, etc. with investigators
    • Presence of an investigator website; Channels used to share information with investigators
    • Types of content shared with investigators by companies not having an investigator website

    II. Access to Investigator Website Portal

    • Types of content shared with investigators via an investigator website
    • Password protection to investigator website/portal
    • Types of investigators and others having access to investigator website
    • Access of website content to different user groups

    III. Communication via Investigator Website Portal

    • Inclusion of website functionality enabling manufacturers to communicate directly with investigators; Inclusion of messaging system on the website allowing investigators to communicate directly with one another